[2] M. D. Tapia et al., “Safety, reactogenicity, and immunogenicity of a chimpanzee

adenovirus vectored Ebola vaccine in children in Africa: A randomised, observer-

blind, placebo-controlled, phase 2 trial,” Lancet Infect. Dis., vol. 20, no. 6,

pp. 719–730, 2020, doi: 10.1016/s1473-3099(20)30019-0

[3] N. Tatsis and H. C. Ertl, “Adenoviruses as vaccine vectors,” Mol. Ther., vol. 10,

no. 4, pp. 616–629, Oct 2004, doi: 10.1016/j.ymthe.2004.07.013

[4] D. M. Knipe, D. Baltimore, and H. F. Lodish, “Separate pathways of maturation of

the major structural proteins of vesicular stomatitis virus,” J. Virol., vol. 21, no. 3,

pp. 1128–1139, 1977, doi: 10.1128/JVI.21.3.1128-1139.1977

[5] E. Sasso, A. M. D’Alise, N. Zambrano, E. Scarselli, A. Folgori, and A. Nicosia,

“New viral vectors for infectious diseases and cancer,” Semin. Immunol., vol. 50,

p. 101430, Aug 2020, doi: 10.1016/j.smim.2020.101430

[6] H. Y. Naim, “Measles virus A pathogen, vaccine, and a vector,” Hum. Vaccines

Immunother, Article; Proceedings Paper vol. 11, no. 1, pp. 21–26, Jan. 2015, doi:

10.4161/hv.34298

[7] K. Ljungberg and P. Liljestrom, “Self-replicating alphavirus RNA vaccines,” Expert

Rev. Vaccines, vol. 14, no. 2, pp. 177–194, Feb. 2015, doi: 10.1586/14760584.2015.

965690

[8] Y. Kaname et al., “Acquisition of Complement Resistance through Incorporation of

CD55/Decay-Accelerating Factor into Viral Particles Bearing Baculovirus GP64,”

J. Virol., vol. 84, no. 7, pp. 3210–3219, Apr 2010, doi: 10.1128/jvi.02519-09

[9] B. Guy, F. Guirakhoo, V. Barban, S. Higgs, T. P. Monath, and J. Lang, “Preclinical

and clinical development of YFV 17D-based chimeric vaccines against dengue,

West Nile and Japanese encephalitis viruses,” Vaccine, vol. 28, no. 3, pp. 632–649,

Jan. 2010, doi: 10.1016/j.vaccine.2009.09.098

[10] B. Guy, M. Saville, and J. Lang, “Development of sanofi pasteur tetravalent dengue

vaccine,” Hum. Vaccines, vol. 6, no. 9, pp. 696–705, 2014, doi: 10.4161/hv.6.9.12739

[11] R. A. Berkeley et al., “Antibody-Neutralized Reovirus Is Effective in Oncolytic

Virotherapy,” Cancer Immunol. Res., vol. 6, no. 10, pp. 1161–1173, Oct. 2018, doi:

10.1158/2326-6066.CIR-18-0309

[12] E. V. Shashkova, M. N. Kuppuswamy, W. S. Wold, and K. Doronin, “Anticancer

activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced

by pharmacologically controlled expression of TRAIL,” Cancer Gene Ther., vol.

15, no. 2, pp. 61–72, Feb. 2008, doi: 10.1038/sj.cgt.7701107

[13] J. L. Imler, “Adenovirus vectors as recombinant viral vaccines,” Vaccine, vol. 13,

no. 13, pp. 1143–1151, Sep .1995, doi: 10.1016/0264-410x(95)00032-v

[14] D. S. Bangari and S. K. Mittal, “Development of nonhuman adenoviruses as vaccine

vectors,” Vaccine, vol. 24, no. 7, pp. 849–862, Feb. 2006, doi: 10.1016/j.vaccine.2

005.08.101

[15] K. Ewer, S. Sebastian, A. J. Spencer, S. Gilbert, A. V. S. Hill, and T. Lambe,

“Chimpanzee adenoviral vectors as vaccines for outbreak pathogens,” Hum. Vaccines

Immunother., vol. 13, no. 12, pp. 3020–3032, 2017, doi: 10.1080/21645515.2017.13

83575

[16] C. Zhang, Y. D. Chi, and D. M. Zhou, “Development of Novel Vaccines Against

Infectious Diseases Based on Chimpanzee Adenoviral Vector,” in Recombinant

Virus Vaccines: Methods and Protocols, vol. 1581, M. C. Ferran and G. R. Skuse

Eds., Humana New York, NY, Methods in Molecular Biology, 2017, pp. 3–13.

[17] A. J. Davison, M. Benko, and B. Harrach, “Genetic content and evolution of adeno-

viruses,” J. Gen. Virol., vol. 84, pp. 2895–2908, Nov. 2003, doi: 10.1099/vir.0.19497-0

[18] T. Steffen et al., “Immunogenicity and efficacy of a recombinant human adenovirus

type 5 vaccine against Zika virus,” Vaccines (Basel), vol. 8, no. 2, Apr. 2020, doi:

10.3390/vaccines8020170

Vectored vaccines

287